Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Myeloid, Chronic-Phase 5Blast Crisis 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × bosutinib × Clear all
NCT01025570 2014-05-09

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

University of California, San Francisco

Phase 1 Terminated
3 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡